Literature DB >> 2285304

Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.

A Z Chaudhry1, C C Knapp, J Sierra-Madero, J A Washington.   

Abstract

The activity of sparfloxacin (CI-978; AT-4140) was compared with those of ofloxacin and ciprofloxacin against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. All 10 ciprofloxacin-resistant staphylococci had reduced susceptibility to sparfloxacin and ofloxacin. Against 105 ciprofloxacin-susceptible strains of S. aureus, the sparfloxacin MIC for 90% of strains tested was at least fourfold lower than those of ciprofloxacin and ofloxacin, while against 104 ciprofloxacin-susceptible strains of S. epidermidis, the MIC of sparfloxacin for 90% of strains tested was twofold lower than that of ciprofloxacin and fourfold lower than that of ofloxacin. MBCs of sparfloxacin were less than or equal to 4 x MICs. The effects of inoculum size and pH variations, as well as the presence of serum, on the MICs of sparfloxacin were minimal. Subinhibitory concentrations of sparfloxacin did reduce adherence of S. epidermidis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285304      PMCID: PMC171945          DOI: 10.1128/AAC.34.9.1843

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Characteristics of adherence to plastic tissue culture plates of coagulase-negative staphylococci exposed to subinhibitory concentrations of antimicrobial agents.

Authors:  K H Schadow; W A Simpson; G D Christensen
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

2.  MBCs for Staphylococcus aureus as determined by macrodilution and microdilution techniques.

Authors:  C J Shanholtzer; L R Peterson; M L Mohn; J A Moody; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.

Authors:  S Nakamura; A Minami; K Nakata; N Kurobe; K Kouno; Y Sakaguchi; S Kashimoto; H Yoshida; T Kojima; T Ohue
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

4.  In vitro activity of AT-4140 against clinical bacterial isolates.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

  4 in total
  8 in total

1.  Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

2.  Activity of new quinolones against ciprofloxacin-resistant staphylococci.

Authors:  G J Forstall; C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

3.  Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.

Authors:  L J Piddock; M Zhu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

5.  Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.

Authors:  J E Fitzgibbon; J F John; J L Delucia; D T Dubin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

6.  In vitro activity of sparfloxacin compared with those of five other quinolones.

Authors:  E Cantón; J Pemán; M T Jimenez; M S Ramón; M Gobernado
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 7.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

8.  In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  K R Smith; C G Cobbs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.